logo
How UAE woman's silent miscarriage inspired a bold new workplace policy

How UAE woman's silent miscarriage inspired a bold new workplace policy

Gulf News22-04-2025

Dubai: Eight years ago, Armin Jamula was managing director at an advertising agency and in the early stages of her first pregnancy. During a routine lunch break, she visited her gynaecologist - only to be informed, in a cold and indifferent tone, that she had suffered a miscarriage.
'I went back to the office and worked for the rest of the day,' she recalled.
Today, Jamula is a mother of two healthy children and the co-founder of ItsHerWay, a UAE-based entrepreneurship platform that empowers women through business funding, career support, and advocacy for workplace equity.
'Before I launched ItsHerWay.com, I was navigating the demands of leadership at an agency that helped shape my entrepreneurial mind set. But the pressure was immense,' she told Gulf News. 'During that time, I went through two back-to-back miscarriages. I will never forget hearing the term 'biochemical loss' for the first time. I was 10.5 weeks pregnant, and in the middle of a packed day, I was told I had lost my baby. That was it.'
It was my first real experience with grief but I never allowed myself to grieve. That silence, that void, and that dismissal of emotional pain in the workplace stayed with me. Years later, with the strength and voice I've gained through ItsHerWay, I knew I had to do something for others like me. That's when the Leave of Absence pledge was born.
Turning grief into advocacy
What stayed with Jamula was not just the pain of the miscarriage, it was the complete absence of space to grieve. She returned to work immediately. She and her husband did not speak about it. No one did.
'Years later, with the voice I found through ItsHerWay, I knew I had to speak up not just for myself, but for others who had been quietly carrying the same weight. That's how the Leave of Absence pledge was born.'
The initiative is the first corporate pledge in the region advocating for formal bereavement leave for employees experiencing a miscarriage. It encourages companies to offer a minimum of seven days of paid leave to employees regardless of gender, who go through pregnancy loss.
Miscarriages are far more common than people think, more than one in five pregnancies globally end in loss, a trend that holds true in the UAE. Yet, 95 per cent of employees in the country who experience miscarriage do not take a single day off work.
'In the workplace, miscarriage is often treated as a clinical event, not an emotional or physical trauma,' Jamula said. 'But it's both. The pain, the bleeding, the hormonal crash, it's overwhelming. A woman needs space to recover biologically and emotionally, and this leave policy offers that space with dignity and empathy.'
The unseen trauma of early miscarriage in the workplace
For many women, early pregnancy is something to hide not celebrate. Workplace culture often discourages disclosure until after the first trimester, and by then, it's too late for many.
According to psychologists, miscarriage isn't just physically painful, it's emotionally devastating. But in many fast-paced industries, women wear a mask of control to be taken seriously.
Social norms reinforce the silence. Many women don't reveal their pregnancies until three months in. So when miscarriage happens early, colleagues and employers often don't even know.
Clinical psychologist Nusrat Khan, who has worked with women for over two decades, witnessed how 'early invisible miscarriages' are dismissed.
'There's a societal belief that early losses don't merit grief. But the reality is that from the moment women see a positive pregnancy test, they begin to build dreams. There's an emotional and visual map already forming,' she said. 'When that ends, it's like a future is taken away. Grief doesn't follow deadlines, and suppressing it to appear professional can lead to anxiety, depression, and emotional numbness.'
Khan explained that unprocessed grief often resurfaces in other areas - relationships, self-esteem, even confidence. 'Many women tie their self-worth to their ability to carry a pregnancy to term. When that's taken away without acknowledgment, it can deeply impact their identity.'
Licensed psychologist Ritasha Varsani added that miscarriage affects not just women, but their partners as well.
'The hormonal changes after loss intensify emotional reactions—ranging from guilt and sadness to anxiety about future pregnancies,' she said. 'If these feelings go unaddressed, they can cause long-term emotional and relational strain.'
Varsani emphasized that while implementing bereavement leave is an important step, what matters just as much is the culture it creates. 'We need to cultivate empathy in the workplace, where people feel truly seen and supported.'
Why a supportive leave policy helps both employees and employers
The impact of bereavement leave goes beyond empathy, it's also good for business.
'By offering miscarriage leave, companies demonstrate they care about employee well-being during a vulnerable time,' said Sarah Brooks, managing director of Fikrah HR. 'It helps reduce stigma around pregnancy loss, builds loyalty, improves morale, and enhances a company's image as a supportive employer.'
She added that firms that have introduced such policies internationally have seen better employee retention and engagement.
Brooks advised companies to draft policies that clearly define pregnancy loss - including miscarriage, stillbirth, ectopic pregnancy, and failed IVF.
'Communication is key. The policy should be shared through multiple platforms, and managers should be trained to respond with compassion and confidentiality,' she said. 'Integrating it with mental health support and flexible work arrangements makes it even more effective.'
By providing dedicated miscarriage bereavement leave, companies demonstrate empathy and support for their staff during a vulnerable time. This not only helps reduce the stigma around pregnancy loss but also supports employee well-being, increases loyalty, and enhances the company's reputation as a compassionate employer. Internationally, organizations that have introduced such policies have reported improved morale and retention, further highlighting the benefits from an HR standpoint.
What the UAE Labour Law currently says about miscarriage leave
Employees are entitled to full maternity leave (45 days paid, 15 days half pay) if the pregnancy is lost after 24 weeks (considered a stillbirth). Additionally, up to 165 days of unpaid leave may be granted in cases of pregnancy-related illness with a valid medical certificate.
'But there's no clear provision for paid leave for miscarriages occurring before 24 weeks,' Brooks said. 'This gap means many employers treat it as regular sick leave or not at all. And although bereavement leave exists, it's not designed for pregnancy loss.'
She noted that in Abu Dhabi Global Market (ADGM), new regulations effective April 2025 will entitle employees to maternity leave in cases of miscarriage or stillbirth after 24 weeks. Dubai International Financial Centre (DIFC), however, currently has no specific rules on miscarriage leave, though some employers in free zones offer support at their discretion.
Globally, there is momentum for change. The UK's proposed Employment Rights Bill, for instance, would require paid leave for pregnancy losses before 24 weeks, a sign of growing recognition.
UAE employers begin to embrace miscarriage leave
'The response has been incredibly moving,' said Jamula. 'Within our ItsHerWay community of more than 7,000 women entrepreneurs, we've seen overwhelming support—from members sharing their own stories to employers stepping up to adopt this change.'
Dr. Seham Asad Ali Khan, co-founder of Aries Dental and Aesthetic Clinic, was among one of the workplaces in the UAE to sign the pledge.
'With a team that's predominantly female, the response was positive and heartfelt. This kind of leave is essential, and I hope more companies follow suit,' she said.
Dr. Khan was inspired to sign after witnessing a family member's struggle. 'I saw how hard it was for them to return to work. Even though early miscarriages are often invisible, the pain both physical and hormonal is very real. This leave gives women the time they need to heal.'
Jamula's goal is to get 100 companies across the UAE and MENA region to sign the Leave of Absence pledge and implement a 7-day bereavement leave policy. She also hopes to run awareness campaigns across media to break the silence around miscarriage.
'Ultimately, I want this to be part of national labour law,' she said. 'But even more than that, I want to see a cultural shift—one where grief, especially women's grief, is never dismissed. One where support is given, not silence.'
'And when my daughter or son joins the workforce someday, I want them to know that if they face such a moment, they won't be expected to push through it quietly. They will be allowed to grieve with dignity, and with support,' Jamula said.

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

New Mayo Venture Partner program announced to accelerate innovation
New Mayo Venture Partner program announced to accelerate innovation

Zawya

timean hour ago

  • Zawya

New Mayo Venture Partner program announced to accelerate innovation

Dubai, United Arab Emirates — Mayo Clinic's Business Development team, consistently recognized as one of the top commercialization operations among academic medical centers, is expanding its capabilities through a new initiative: the Mayo Venture Partner (MVP) program. In response to the dynamic and evolving healthcare landscape, Mayo Clinic is enlisting industry veterans to create groundbreaking technologies, co-invest in aligned companies and build new ventures from the ground up. The MVP program brings together seasoned entrepreneurs, investors and executives who will leverage their expertise with Mayo Clinic's world-class research and clinical expertise. These leaders will play a pivotal role in identifying high-potential opportunities across Mayo Clinic's research and clinical practices, forming new companies and accelerating innovations that advance patient care. The inaugural MVPs are: Amy DuRoss — Healthcare innovation leader with deep expertise in policy, commercialization and diagnostics. Audrey Greenberg — Company builder, executive leader and expert in launching and scaling ventures across life sciences, healthcare and other industries. Brian Poger — Serial entrepreneur and venture strategist with a track record in digital health and healthcare services. Working in close partnership with the Mayo Clinic Business Development team, the MVPs will help forge strategic collaborations and deliver real-world impact, underscoring Mayo Clinic's enduring commitment to transforming healthcare. To date, the Business Development team has returned more than $1.2B in revenue to Mayo Clinic to support its clinical practice, education and research. Additionally, the team has helped create more than 180 companies, licensed 4,848 Mayo Clinic-created technologies through 2,913 agreements, and issued 4,159 patents. This program and these efforts align with Mayo Clinic's vision to transform healthcare by: Accelerating innovation — Turning cutting-edge research, data and other resources into real-world solutions for patients. Enhancing patient care — Bringing new treatments and technologies to patients that offer cures and the ability to connect with the healthcare system in ways that increase access and decrease costs. Building strategic partnerships — Leveraging external expertise and resources to amplify impact. Mayo Clinic is dedicated to driving progress and expanding its impact through innovation. This initiative is an exciting opportunity for investors, CEOs and innovators to collaborate with Mayo Clinic and be part of a future that prioritizes patient-centric, transformative healthcare solutions. To learn more, visit the Mayo Clinic Business Development website and subscribe to its e-newsletter and follow the Mayo Clinic Ventures LinkedIn page.

‘Not a magic solution': UAE doctors warn of surging off-label use of Ozempic, Mounjaro for weight loss
‘Not a magic solution': UAE doctors warn of surging off-label use of Ozempic, Mounjaro for weight loss

Arabian Business

time2 hours ago

  • Arabian Business

‘Not a magic solution': UAE doctors warn of surging off-label use of Ozempic, Mounjaro for weight loss

Doctors in the United Arab Emirates are warning against the growing off-label use of diabetes medications such as Ozempic and Mounjaro for weight loss, as demand surges among individuals who are neither diabetic nor clinically obese. Originally developed to treat type 2 diabetes, GLP-1 receptor agonists – semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound) – are now increasingly being used for aesthetic weight loss purposes in the UAE, reflecting a broader global phenomenon that experts say may be spiralling beyond medical control. 'Some are seeking these medications purely for weight loss,' Dr Tony Joseph, a specialist endocrinologist at Burjeel Day Surgery Center in Al Shahama, told Arabian Business. 'For patients without obesity or metabolic disease, the risk-benefit ratio is unclear.' Joseph added that while prescriptions in his clinic remain within approved indications – obesity (a Body Mass Index of 30 or higher, or 27 or higher in individuals with weight-related comorbidities) and type 2 diabetes – the uptick in off-label interest has been notable. The medications have rapidly gained popularity due to their visible results, with some patients losing more than 15 per cent of body weight in under a year. But healthcare professionals are urging caution. The misuse of these drugs outside clinical guidelines may expose some to side effects ranging from nausea and gastrointestinal discomfort to more serious complications such as pancreatitis, gallbladder issues, and potential muscle loss. 'Long-term safety in non-obese individuals has not been well established in clinical trials,' Joseph said. 'We advise caution.' Social media hype fueling 'quick fix' culture Clinical dietitians say the surge in demand is being driven not by medical referrals, but by viral social media content glamorising the drugs as easy, injectable solutions to weight loss. 'Few social media platforms have glamorised these drugs, often portraying them as magical solutions,' Ruqsar Rahman, a clinical dietitian at Burjeel Hospital in Abu Dhabi, told Arabian Business. 'This undermines the importance of long-term nutrition and physical activity.' Rahman noted a marked shift in how patients approach weight loss, with more inquiries about pharmaceuticals and fewer about dietary planning or physical training. 'The availability of these drugs has created the perception of a quick fix,' she said. 'We're seeing people bypass the fundamentals – like sustainable eating and movement – in favour of weekly injections.' Dependency and weight regain risks Even when prescribed appropriately, GLP-1 receptor agonists pose another challenge: maintaining weight loss once treatment stops. Both Joseph and Rahman have observed patients regaining weight after discontinuation, particularly if lifestyle changes weren't made in parallel. 'Without long-term behaviour change, weight regain is typical once the medication is stopped,' said Joseph. 'This is one of the biggest challenges we face in practice.' Rahman likens the pattern to crash dieting, with dramatic short-term results often followed by a swift return to previous weight. 'When individuals haven't built sustainable habits to support the weight loss, the weight often returns,' she said. 'The drugs should be a stepping stone, not a lifelong crutch.' Clinical promise – if used ethically Despite concerns about misuse, both experts emphasised that GLP-1 drugs represent a genuine breakthrough in treating obesity – particularly in regions like the Gulf, where sedentary lifestyles and diet-related diseases are widespread. 'These medications are not a silver bullet, but they are a powerful tool,' Joseph said. 'They help bridge the gap where lifestyle interventions alone have had limited success.' Used within a comprehensive care plan that includes dietary support, physical activity, and mental health counselling, the drugs can help patients achieve long-term success. At his clinic, Joseph refers eligible patients to a multidisciplinary team to ensure a tailored and safe weight management strategy. Rahman agreed, adding that the drugs should be framed as part of an evidence-based medical toolkit, not as cosmetic enhancements. 'When paired with improved nutrition, exercise, and emotional health support, the outcomes can be dramatically improved,' she said. 'But if we position them as cultural shortcuts, we do more harm than good.' The UAE Ministry of Health and Prevention (MOHAP) has reiterated that GLP-1 drugs are prescription medications and should only be used under medical supervision. Physicians are required to follow established clinical protocols, including those issued by the American Diabetes Association (ADA) and the European Association for the Study of Obesity (EASO). As interest in weight-loss injections continues to grow, doctors in the Emirates are calling for stronger regulation, better patient education, and a renewed focus on prevention over treatment. 'Obesity is a chronic, relapsing disease with both biological and environmental drivers,' Joseph said. 'The emergence of practical pharmacological tools is welcome, but we must ensure they are used responsibly, ethically, and with patient safety as the top priority.'

CorroHealth makes strategic investment in Gulf Capital's Santechture
CorroHealth makes strategic investment in Gulf Capital's Santechture

Zawya

time2 hours ago

  • Zawya

CorroHealth makes strategic investment in Gulf Capital's Santechture

Abu Dhabi – Gulf Capital, one of the largest private equity firms investing from the GCC to the rest of Asia, announced today that global healthcare technology company CorroHealth has made a strategic investment into one of its portfolio companies, Santechture, a Dubai based pioneering revenue cycle management (RCM) intelligent technology solutions provider. The deal brings together the industry-leading AI capabilities of CorroHealth with the advanced RCM solutions of SANTECHTURE, equipping SANTECHTURE healthcare clients across the Gulf Cooperation Council (GCC) region with powerful new technology to maximize ROI. The investment formalizes what has been a productive working relationship between the two companies. Over the past two years, CorroHealth and SANTECHTURE have successfully completed multiple proofs of concept for SANTCEHTURE clients. In January, SANTECHTURE and CorroHealth jointly hosted the Arab Health reception focused on AI and Revenue Cycle Management (RCM) Innovation. SANTECHTURE, which is backed by leading institutional investors Gulf Capital and Shorooq Partners, has seen a phenomenal increase in demand for its advanced deep tech RCM solutions in the GGC and across regional markets, and this partnership will support yet another leap ahead in advancing innovation and value creation. CorroHealth CEO Pat Leonard said, 'This is an exciting step forward for CorroHealth, as we combine our technological capabilities with a local company based in the GCC region. CorroHealth joining forces with SANTECHTURE brings the best of both worlds to provide clients in the region with unsurpassed RCM capabilities to protect hospitals' bottom lines and help to ensure their financial future.' SANTECHTURE Founder and CEO Anas Batikhi said, 'The pairing of SANTECHTURE's unique leading-edge solutions with CorroHealth's AI driven innovations in the RCM technology space is truly unrivalled. We are especially thrilled to be cementing further our working relationship with CorroHealth and leading the intelligent automation drive to support our clients and partners with their RCM digital transformation journey, delivering on cost reduction and improved revenue outcomes.' Gulf Capital Managing Director Mohammad Madani added, 'We are proud to have been early backers of SANTECHTURE and to now support this landmark partnership between SANTECHTURE's and CorroHealth. This strategic investment is a strong validation of SANTECHTURE's leadership in intelligent RCM solutions across the GCC and marks a pivotal milestone in its growth journey. We are confident this collaboration will unlock significant value for healthcare providers in the region.' Bilal Mushtaq, MD, CorroHealth's Executive Vice President of Global Growth and Strategy for GCC market expansion said 'This strategic investment and partnership marks a pivotal step forward in our growth strategy, reinforcing our commitment to innovation and delivering greater value to a new market. This is not just a collaboration but a shared vision to forge a new path towards providing excellence in revenue cycle management'

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store